ERNA
HEALTHCAREErnexa Therapeutics Inc
$6.04+2.05 (+51.38%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ERNA Today?
No stock-specific AI insight has been generated for ERNA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.18$101.25
$6.04
Fundamentals
Market Cap$7M
P/E Ratio—
EPS$-56.00
Dividend Yield—
Dividend / Share—
ROE-6.9%
Profit Margin—
Debt / Equity—
Trading
Volume64.1M
Avg Volume (10D)—
Shares Outstanding1.2M
ERNA News
20 articles- Ernexa Therapeutics (ERNA) Preclinical Data Shows 100% Survival and Complete Tumor Clearance in Ovarian Cancer ModelsAdvfn·May 6, 2026
- Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer ModelsYahoo Finance·May 6, 2026
- Ernexa Therapeutics Announces 1-for-25 Reverse Stock SplitYahoo Finance·Apr 30, 2026
- Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026Yahoo Finance·Mar 31, 2026
- Ernexa Therapeutics to Participate in Virtual Investor Closing Bell SeriesYahoo Finance·Feb 20, 2026
- Ernexa Therapeutics Announces Pricing of $10.5 Million Public OfferingYahoo Finance·Feb 6, 2026
- Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDAYahoo Finance·Feb 3, 2026
- Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration ProgramYahoo Finance·Jan 27, 2026
- Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian CancerYahoo Finance·Jan 6, 2026
- Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian CancerYahoo Finance·Dec 8, 2025
- Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual MeetingYahoo Finance·Dec 3, 2025
- Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOGYahoo Finance·Dec 2, 2025
- Ernexa Therapeutics to Present at Oxford Global’s Cell 2025Yahoo Finance·Nov 11, 2025
- Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy TrialsYahoo Finance·Nov 10, 2025
- Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” PlatformYahoo Finance·Nov 6, 2025
- /C O R R E C T I O N -- Cellipont Bioservices/Yahoo Finance·Oct 29, 2025
- BC-Most Active StocksYahoo Finance·Oct 29, 2025
- Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the MesaYahoo Finance·Oct 1, 2025
- Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development SummitYahoo Finance·Sep 29, 2025
- Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer ResearchYahoo Finance·Sep 17, 2025
All 20 articles loaded
Price Data
Open$5.85
Previous Close$3.99
Day High$6.94
Day Low$4.57
52 Week High$101.25
52 Week Low$3.18
52-Week Range
$3.18$101.25
$6.04
Fundamentals
Market Cap$7M
P/E Ratio—
EPS$-56.00
Dividend Yield—
Dividend / Share—
ROE-6.9%
Profit Margin—
Debt / Equity—
Trading
Volume64.1M
Avg Volume (10D)—
Shares Outstanding1.2M
About Ernexa Therapeutics Inc
Brooklyn ImmunoTherapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat cancer patients. The company is headquartered in Brooklyn, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—